Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. - Cannon CP; Husted S; Harrington RA; Scirica BM; Emanuelsson H; Peters G; Storey RF; DISPERSE-2 Investigators (Journal of the American College of Cardiology (JACC), 2007)